<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The association of <z:hpo ids='HP_0004818'>paroxysmal nocturnal hemoglobinuria</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e>) and <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (AA) raises the yet unresolved questions as to whether these two disorders are different forms of the same disease </plain></SENT>
<SENT sid="1" pm="."><plain>We compared two groups of patients with respect to cytogenetic features, <z:chebi fb="0" ids="24410">glycosylphosphatidylinositol</z:chebi> (GPI)-linked protein expression, protein C/protein S/thrombomodulin/antithrombin III activity, and PIG-A gene expression </plain></SENT>
<SENT sid="2" pm="."><plain>The first group consisted of eight patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> (defined as positive Ham and <z:chebi fb="27" ids="17992">sucrose</z:chebi> tests at diagnosis), and the second, 37 patients with AA </plain></SENT>
<SENT sid="3" pm="."><plain>Twelve patients with AA later developed a <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> clone </plain></SENT>
<SENT sid="4" pm="."><plain>Monoclonal antibodies used to study GPI-linked protein expression (CD14 [on monocytes], CD16 [on neutrophils], CD48 [on lymphocytes and monocytes], CD67 [on neutrophils and eosinophils], and, more recently, CD55, CD58, and CD59 [on erythrocytes]) were also tested on a cohort of 20 <z:mpath ids='MPATH_458'>normal</z:mpath> subjects and five patients with constitutional AA </plain></SENT>
<SENT sid="5" pm="."><plain>Ham and <z:chebi fb="27" ids="17992">sucrose</z:chebi> tests were performed on the same day as flow-cytometric analysis </plain></SENT>
<SENT sid="6" pm="."><plain>Six of 12 patients with AA, who secondarily developed a <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> clone, had clinical symptoms, while <z:hpo ids='HP_0000001'>all</z:hpo> eight patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> had <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> and/or <z:mp ids='MP_0005048'>thrombosis</z:mp> and/or <z:hpo ids='HP_0001878'>hemolytic anemia</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Cytogenetic features were <z:mpath ids='MPATH_458'>normal</z:mpath> in <z:hpo ids='HP_0000001'>all</z:hpo> but two patients </plain></SENT>
<SENT sid="8" pm="."><plain>Proteins C and S, thrombomodulin, and antithrombin III levels were within the <z:mpath ids='MPATH_458'>normal</z:mpath> range in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> and in those with AA (with or without a <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> clone) </plain></SENT>
<SENT sid="9" pm="."><plain>In patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e>, CD16 and CD67 expression were deficient in 78% to 98% of the cells and CD14 in 76% to 100% </plain></SENT>
<SENT sid="10" pm="."><plain>By comparison, a GPI-linked defect was detected in 13 patients with AA, affecting a mean of 32% and 33% of CD16/CD67 and CD14 cell populations, respectively </plain></SENT>
<SENT sid="11" pm="."><plain>Two of three tested patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> and 1 of 12 patients with AA had a defect in the CD48 lymphocyte population </plain></SENT>
<SENT sid="12" pm="."><plain>In a follow-up study of our patient cohort, we used the GPI-linked molecules on granulocytes and monocytes investigated earlier and added the study of CD55, CD58, and CD59 on erythrocytes </plain></SENT>
<SENT sid="13" pm="."><plain>Two patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> and 14 with AA were studied for 6 to 13 months after the initial study </plain></SENT>
<SENT sid="14" pm="."><plain>Among patients with AA, four in whom no GPI-anchoring defect was detected in the first study had no defect in follow-up studies of <z:hpo ids='HP_0000001'>all</z:hpo> blood-cell subsets (including erythrocytes) </plain></SENT>
<SENT sid="15" pm="."><plain>Analysis of granulocytes, monocytes, and erythrocytes was performed in 7 of 13 AA patients in whom affected monocytes and granulocytes were previously detected </plain></SENT>
<SENT sid="16" pm="."><plain>A GPI-anchoring defect was detected on erythrocytes in five of six.(ABSTRACT TRUNCATED AT 400 WORDS) </plain></SENT>
</text></document>